Hospitalist Doctors in Olympia Fields, IL Accepting Medicare

7 Hospitalist doctors found. Showing 1 - 7

Dr. Shil Urvish Punatar, D.O. Hospitalist Medicare: Medicare Enrolled Practice Location: 20201 Crawford Ave, Olympia Fields, IL 60461 Phone: 708-747-4000

Nicholas John Zanghi, Hospitalist Medicare: Medicare Enrolled Practice Location: 20201 Crawford Ave, Olympia Fields, IL 60461 Phone: 708-747-4000

Sarah A Monaghan, DO Hospitalist Medicare: Medicare Enrolled Practice Location: 20201 Crawford Ave, Olympia Fields, IL 60461 Phone: 708-747-4000

Dr. Mateusz Dawid Gorecki, DO Hospitalist Medicare: Medicare Enrolled Practice Location: 20201 Crawford Ave, Attn: Postdoctoral Education, Olympia Fields, IL 60461 Phone: 708-747-4000

Dr. Mohammed Sadique Hussain, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 20201 Crawford Ave, Olympia Fields, IL 60461 Phone: 708-855-7297    Fax: 708-679-2161

Dr. Rakesh K Chugh, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 20201 Crawford Ave, Olympia Fields, IL 60461 Phone: 844-740-4445    Fax: 708-679-2161

Brandon Scott, D.O. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 20201 Crawford Ave, Olympia Fields, IL 60461 Phone: 708-747-4000    Fax: 708-503-3241

News Archive

Health care politics: Perry's stem cell controversy, presidential contenders and health law; Biden Medicare fact check

Texas Gov. Rick Perry, who recently underwent an experimental injection of his own adult stem cells to relieve back pain, pushed a bill through the Legislature in June that paves the way for a company co-owned by his doctor to become the first state-approved "bank" to store and cultivate such cells for medical treatment that fact illustrates two aspects of his record that are drawing increasing attention as he pursues the presidency: his enthusiasm for ideas that are sometimes outside the scientific mainstream and what critics view as his willingness to use the levers of state government to benefit friends and political benefactors.

Genzyme updates on Cerezyme supply plus 2009 financials

Genzyme Corporation (NASDAQ: GENZ) today provided an update on the impact of Cerezyme® (imiglucerase for injection) supply constraints on patient treatment regimens and on the company's 2009 financial results. The company's Fabrazyme® (agalsidase beta) supply constraint period, Fabrazyme dose conservation guidelines for patients, and Fabrazyme financial guidance are unchanged.

University of Kentucky receives $12.2 million grant to reduce negative health from hazardous chemicals

The University of Kentucky has received a $12.2 million grant from the National Institutes of Health to continue its work to better understand and minimize negative health and environmental impacts from hazardous waste sites.

Beta-blockers show anti-inflammatory effects in cirrhosis

Approximately 170,000 people die every year in Europe from the direct consequences of advanced chronic liver disease (cirrhosis).

Early cholesterol-lowering drug therapy reduces artery-clogging plaque

Early cholesterol-lowering drug therapy after hospitalization for acute coronary syndrome appears to reduce artery-clogging plaque, according to a study reported in Circulation: Journal of the American Heart Association.

Read more Medical News

› Verified 5 days ago